10:49 AM EDT, 07/08/2025 (MT Newswires) -- Eupraxia Pharmaceuticals ( EPRX ) on Tuesday announced the dosing of the first patient in the Phase 2b randomized, placebo-controlled portion of the RESOLVE clinical trial evaluating EP-104GI, an investigational treatment for eosinophilic esophagitis (EoE), an inflammatory disease in which white blood cells migrate to the esophagus, resulting in pain and difficulty swallowing food.

The company plans to enroll a minimum of 60 patients in the Phase 2b portion of the RESOLVE study in up to 25 sites globally, assessing tissue health measured by biopsy, symptom scores, and safety, over a twelve-month period. The Phase 2b study will be comprised of one placebo and two separate active doses of EP-104GI.

During the Phase 2b portion of the RESOLVE study, Eupraxia will continue to report additional data from patients that were entered into the open-label Phase 2a study, with further data from cohorts 5-8 available in early September and November. The company expects topline data from the Phase 2b portion of the RESOLVE study by third quarter of 2026.

Shares of the company were last seen down 1.3% at $7.50 on the Toronto Stock Exchange.

Price: 7.49, Change: -0.11, Percent Change: -1.45